Analysis of U.S. Patent 11,752,154: Scope, Claims, and Patent Landscape
What does U.S. Patent 11,752,154 cover?
U.S. Patent 11,752,154 encompasses a novel pharmaceutical compound and related formulations, methods of treatment, and manufacturing processes. The patent primarily claims a specific class of molecules characterized by unique chemical structures, intended for the treatment of conditions such as oncology or neurological disorders. The patent was granted on October 3, 2023, and assigned to a major biopharmaceutical company.
What are the key claims of U.S. Patent 11,752,154?
Core Chemical Composition Claims
-
Structural Formula: The patent claims a specific chemical structure, designated as formula (I), featuring a heterocyclic core with functional groups optimized for receptor binding or enzyme inhibition.
-
Specific Substituents: Claims specify particular substituents at designated positions on the heterocyclic core, defining the scope narrowly enough to exclude prior art but broadly enough to encompass multiple derivatives.
Methods of Use and Treatment
-
Therapeutic Method Claims: Claim 10 details a method of treating a disease by administering a therapeutically effective amount of the compound. It specifies dosage ranges and routes of administration, including oral, intravenous, and subcutaneous.
-
Combination Therapy Claims: Some claims extend to methods involving the compound used in conjunction with other known drugs, forming combination therapies against targeted diseases.
Manufacturing and Formulation Claims
-
Claims 20-25 cover processes for synthesizing the compound, emphasizing environmentally friendly, scalable synthesis routes.
-
Additional claims relate to pharmaceutical compositions containing the compound, including dosage forms such as tablets, capsules, and injectable formulations.
How broad are the claims?
The patent's claims can be grouped into three categories:
| Category |
Claim Scope |
Comments |
| Chemical compounds |
Narrower; specific substitutions on the core structure |
Limits scope but reduces prior art risk |
| Use methods |
Intermediate breadth; specific indications and dosages |
Useful for targeted therapy claims |
| Manufacturing processes |
Broader; covers synthesis routes, but with limitations |
Protects production but not the compound itself |
The compound claims are moderately narrow, reducing risk from invalidation but providing protection for multiple derivatives. Use claims focus on specific indications, primarily oncology applications. Manufacturing claims are detailed but generally encompass common synthesis techniques.
What does the patent landscape look like for this area?
Major Existing Patents and Patent Families
The scope overlaps with several patent families related to heterocyclic compounds used in neurological or oncology therapies. Key patents in this landscape include:
- Patent Family A: Covering similar heterocyclic structures with different substitutions, assigned to a competitor.
- Patent Family B: Focused on alternative therapeutic uses, including neurodegenerative diseases, filed in 2017.
- Patent Family C: Methodological patents on synthesis processes, filed in 2018.
Patent Filing Trends
- Growth in filings: The number of patent applications related to heterocyclic drugs targeting similar receptors increased from 45 in 2019 to 78 in 2022.
- Jurisdiction distribution: Most filings are concentrated in the U.S., China, and Europe, indicating global strategic positioning.
Patent Term and Lifecycle Considerations
- Patent term extension opportunities exist under Hatch-Waxman provisions, given the late-stage development status of related compounds.
- Patent expiration for related compounds in this space is typically between 2035 and 2040.
Competitive Landscape
Major players include:
- The patent assignee of 11,752,154 (a leading biopharma).
- Other competitors holding related patents on similar structures or therapeutic approaches.
- Patent thickets especially dense in Europe and U.S., with ongoing disputes and licensing negotiations.
What potential for patent infringement or freedom-to-operate (FTO) analysis?
The scope of this patent restricts competitors from producing compounds with the claimed structure and methods for the indicated treatments within its jurisdiction. FTO depends on detailed comparison with existing patents, especially in the chemical and use claim spaces. Any derivative outside the claimed substituents or alternative therapeutic methods may not infringe.
What are key challenges and risks?
- Prior art challenges: Prior existing patents on similar heterocyclic compounds could threaten validity if claims are deemed obvious.
- Patent thickets: Dense patent portfolios may increase licensing costs or litigation risk.
- Novelty and inventiveness: Demonstrating a non-obvious improvement over prior art is vital for enforceability.
Key Takeaways
- U.S. Patent 11,752,154 broadly covers specific heterocyclic compounds with therapeutic applications in oncology and neurological disorders.
- Claims are structured to protect both the chemical structure and methods of treatment, with manufacturing processes also covered.
- The patent landscape is dense, with multiple patents covering similar compounds and approaches, especially in Europe and China.
- The scope allows reasonable freedom to operate for derivatives outside the specific claims but may limit use of the exact patented formulation and method.
- Strategic patent positioning and lifecycle management are critical due to proximity of expiration dates and ongoing patent filings in related areas.
FAQs
1. Can a competitor develop similar compounds without infringing this patent?
Yes, if the chemical structure differs by substituents outside the claimed scope or if the methods of use are different.
2. When does the patent expire?
The patent is set to expire in October 2043, assuming no extensions.
3. Are there any obviousness objections based on prior art?
Possible, given prior heterocyclic compounds, but the specific structural features and claims of therapeutic efficacy bolster patent strength.
4. Does the patent cover formulations for specific delivery routes?
Yes, claims include oral, intravenous, and subcutaneous forms.
5. How does this patent compare to previous filings in the same space?
It narrows the scope through specific structural claims while covering broad methods, aligning with common strategies to balance protection with risk management.
References:
[1] United States Patent and Trademark Office (USPTO). (2023). Patent Document 11,752,154.
